scispace - formally typeset
L

Leocadio Rodríguez-Mañas

Researcher at Carlos III Health Institute

Publications -  317
Citations -  15907

Leocadio Rodríguez-Mañas is an academic researcher from Carlos III Health Institute. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 55, co-authored 271 publications receiving 11324 citations. Previous affiliations of Leocadio Rodríguez-Mañas include European University of Madrid & Foundation for Biomedical Research.

Papers
More filters

Cardiovascular risk and diabetes in old people

TL;DR: An increasing proportion of patients are older and in this group current approaches to cardiovascular risk estimation may not be the most suitable, so the way to tackle them must follow a global strategy.
Journal ArticleDOI

Erratum to: Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

Jean Bousquet, +297 more
TL;DR: The authors would like to change and use the correct name of M. Khaitov which is M.Kaitov on this manuscript because the authors have incorrectly used her other name during the finalization of this research.
Journal ArticleDOI

Higher sRAGE Levels Predict Mortality in Frail Older Adults with Cardiovascular Disease.

TL;DR: Frailty status influences the relationship between sRAGE and mortality in older adults with CVD, and s RAGE could be used as a prognostic marker of mortality for these individuals, particularly if they are also frail.
Journal ArticleDOI

[Effectiveness and efficiency of acute geriatric units: A classic topic revisited].

TL;DR: A meta-analysis on the subject has recently been published in Age and Aging, which adds six new studies to the five clinical trials analyzed in previous meta-analyses as mentioned in this paper .
Journal ArticleDOI

Pharmacological interference of vascular smooth muscle cell hypertrophy induced by glycosylated human oxyhaemoglobin.

TL;DR: Drugs with powerful antioxidant properties, especially carvedilol and gliclazide, are particularly effective in preventing glycosylated human oxyhaemoglobin-induced vascular smooth muscle cell hypertrophy.